Cituximab buys more time for some people with advanced colorectal cancerBMJ 2007; 335 doi: http://dx.doi.org/10.1136/bmj.335.7629.1071 (Published 22 November 2007) Cite this as: BMJ 2007;335:1071
Traditional cytotoxic treatments for cancer preferentially kill rapidly dividing cells. More recently, researchers have turned their attention to the growth factors expressed by some cancers, targeting them with specifically designed monoclonal antibodies. Cituximab is one such antibody, directed against the epidermal growth …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial